An in vitro BRAF activation assay elucidates molecular mechanisms driving disassembly of the autoinhibited BRAF state

• 成果类型: Article
• 署名作者: Ritt, Daniel A.; Durrant, David E.; Drew, Matthew R.; Sandin, Suzanne I.; Fiesco, Juliana A. Martinez; Zhang, Xiaohua; Aydin, Fikret; Carpenter, Timothy S.; Scheidemantle, Grace M.; D'Ippolito, Robert A.; Sohn, Alexandria L.; Dehart, Caroline J.; Shrestha, Rebika; Snead, Kelly; Hull, Jenna; Tempkin, Jeremy O. B.; Yang, Yue; Lightstone, Felice C.; Streitz, Frederick H.; Zhang, Ping; Turbyville, Thomas J.; Stephen, Andrew G.; Esposito, Dominic; Ingolfsson, Helgi I.; Nissley, Dwight, V; Morrison, Deborah K.
• 署名单位: National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Frederick National Laboratory for Cancer Research; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Energy (DOE); Lawrence Livermore National Laboratory
• 刊物名称: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
• ISSN/ISSBN: 0027-14249
• DOI: 10.1073/pnas.2508169122
• 发表日期: 2025-09-15
• 关键词: quantitative-analysis; cause noonan; ras-binding; mutations; complex; domain; raf-1; dimerization; p21(ras); kinases

摘要

The RAF kinases (ARAF, BRAF, and CRAF) are essential components of the RAS-ERK signaling pathway, which controls vital cellular processes and is frequently dysregulated in human disease. Notably, mutations that alter BRAF function are prominent drivers of human cancer and certain RASopathy disorders, making BRAF an important target for therapeutic intervention. Despite extensive research, several aspects of BRAF regulation remain unclear. In this study, we developed an in vitro BRAF activation assay using purified autoinhibited BRAF:14-3-32:MEK complexes. Our results show that fully processed, active-state KRAS alone can promote dimer-dependent BRAF activation. Moreover, we found that phosphatidylserine (PS)-containing liposomes synergized with KRAS to promote BRAF activation, achieving activity levels comparable to those observed with BRAF proteins that constitutively dimerize. In contrast, the SMP phosphatase complex had only a minimal effect on BRAF catalytic activity in this system but mediated the dephosphorylation of the negative regulatory pS365 14-3-3 binding site in a manner that was accelerated by the presence of KRAS alone or KRAS and 30% PS liposomes. Finally, we show that inhibitors blocking the BRAF RBD:KRAS interaction were able to suppress the in vitro activation of BRAF, underscoring the critical role of RAS binding in initiating the disassembly of the BRAF autoinhibited state. Thus, this assay provides valuable insights into the steps required for BRAF activation and can serve as an effective screening tool for identifying compounds that may inhibit this process and have therapeutic potential.